Immunopathology &...
Follow
Find
7.2K views | +1 today
Immunopathology & Immunotherapy
Latest advances in immunopathology diagnosis and treatment
Curated by Alfredo Corell
Your new post is loading...
Your new post is loading...
Scooped by Alfredo Corell
Scoop.it!

KEY ADVANCES IN MEDICINE by Nature Reviews journals

KEY ADVANCES IN MEDICINE by Nature Reviews journals | Immunopathology & Immunotherapy | Scoop.it
Alfredo Corell's insight:

Including Immunology (pathology and therapies) topics:


  • 29 TYpE 2 DiAbETES MElliTUS | A central role of the gut in glucose homeostasis; Geltrude Mingrone and Lidia Castagneto-Gissey
  • 30 METAbOliSM | The gut microbiota manages host metabolism; Patrice D. Cani
  • 35 hEpATiTiS C | HCV causes systemic disorders that can be cured; Francesco Negro
  • 37 fAECAl MiCRObiOTA TRANSplANTATiON | Developing human gut microbiota as a class of therapeutics; Alexander Khoruts
  • 38 COEliAC DiSEASE | New insights in dietary-gluten-induced autoimmunity; Katri Kaukinen and Markku Mäki
  • 42 ibD | Enriching the therapeutic armamentarium for IBD;  Silvio Danese and Laurent Peyrin-Biroulet
  • 51 TRANSplANTATiON iMMUNOlOgY | New approaches to diagnosis of rejection; Nicholas A. Zwang and Laurence A. Turka
  • 65 MUlTiplE SClEROSiS | Novel triggers, treatment targets and brain atrophy measures; Xavier Montalban and Mar Tintoré
  • 71 SYSTEMiC lUpUS ERYThEMATOSUS | Taking a closer look at biologic therapy for SLE; David A. Isenberg and Anisur Rahman
  • 72 EpigENETiCS | DNA methylation and miRNA—key roles in systemic autoimmunity; Bruce C. Richardson and Dipak R. Patel
  • 74 RhEUMATOiD ARThRiTiS | Translational medicine in RA—time for change; Pierre Miossec


more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

The Global Burden of Cancer 2013

The Global Burden of Cancer 2013 | Immunopathology & Immunotherapy | Scoop.it
Using Global Burden of Disease (GBD) 2013 methodology, the GBD Cancer Collaboration investigators estimate mortality, incidence, years lived with disability, years of life lost, and disability-adjusted life years for 28 cancers in 188 countries by sex from 1990 to 2013.
Alfredo Corell's insight:

Conclusions and Relevance  Cancer poses a major threat to public health worldwide, and incidence rates have increased in most countries since 1990. The trend is a particular threat to developing nations with health systems that are ill-equipped to deal with complex and expensive cancer treatments. The annual update on the Global Burden of Cancer will provide all stakeholders with timely estimates to guide policy efforts in cancer prevention, screening, treatment, and palliation.


JAMA Oncol. Published online May 28, 2015. doi:10.1001/jamaoncol.2015.0735


more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications

Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications | Immunopathology & Immunotherapy | Scoop.it

In this review, we will dissect the microbial actors thought to be involved in the HH as well as their immunomodulatory mechanisms as emphasized by experimental studies, with a particular attention on parasites. Thereafter, we will review the early clinical trials using helminthes’ derivatives focusing on autoimmune diseases.

Alfredo Corell's insight:

Background

The Hygiene Hypothesis (HH) attributes the dramatic increase in autoimmune and allergic diseases observed in recent decades in Western countries to the reduced exposure to diverse immunoregulatory infectious agents. This theory has since largely been supported by strong epidemiological and experimental evidence.



BMC Medicine 2015, 13:81  doi:10.1186/s12916-015-0306-7

The electronic version of this article is the complete one and can be found online at:http://www.biomedcentral.com/1741-7015/13/81

more...
BrainImmune's comment, May 5, 4:46 AM
you are welcome Alfredo
Alfredo Corell's comment, May 5, 6:03 PM
:)
Scooped by Alfredo Corell
Scoop.it!

Penn Medicine Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

Penn Medicine Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize | Immunopathology & Immunotherapy | Scoop.it
University of Pennsylvania cancer and HIV expert Carl June, MD, has been named one of two recipients of the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in cancer immunotherapy. Since 1952, the Paul Ehrlich and Ludwig Darmstaedter Prize has been awarded to scientists who have made great advancements in the fields in which Paul Ehrlich worked, in particular immunology, cancer research, microbiology, and chemotherapy.
Alfredo Corell's insight:

He is widely recognized as leader of the team responsible for the first successful and sustained demonstration of the use of CAR T cell therapy, an investigational approach in which a patient’s cells are removed through an apheresis process similar to dialysis and modified in Penn's cell and vaccine production facility. Scientists there reprogram the patients’ T cells through a gene modification technique using a viral vector that trains them to recognize specific types of cancer cells. The modified cells – known as chimeric antigen receptor (CAR) T cells –  are then infused back into the patient's body, where they multiply, hunt and attack tumor cells.

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Rare Disease Day 2015 - Feb 28 - Download and share our communication materials

Rare Disease Day 2015 - Feb 28 - Download and share our communication materials | Immunopathology & Immunotherapy | Scoop.it
Be part of the international movement and use the Rare Disease Day official international communication materials found here!
Alfredo Corell's insight:

Primary Immunodeficiencies are also among the Rare diseases. Thus, please... share the communication materials about the Rare Diseases Day :)

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

How do vaccines work? - nice animation by Kelwalin Dhanasarnsombut -

How do vaccines work? - nice animation by Kelwalin Dhanasarnsombut - | Immunopathology & Immunotherapy | Scoop.it
View full lesson: http://ed.ted.com/lessons/how-do-vaccines-work-kelwalin-dhanasarnsombut The first ever vaccine was created when Edward Jenner, an English p...
more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions : Nature : Nature Publishing Group

Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions : Nature : Nature Publishing Group | Immunopathology & Immunotherapy | Scoop.it
Mast cells are primary effectors in allergic reactions, and may have important roles in disease by secreting histamine and various inflammatory and immunomodulatory substances. Although they are classically activated by immunoglobulin (Ig)E antibodies, a unique property of mast cells is their antibody-independent responsiveness to a range of cationic substances, collectively called basic secretagogues, including inflammatory peptides and drugs associated with allergic-type reactions. The pathogenic roles of these substances have prompted a decades-long search for their receptor(s). Here we report that basic secretagogues activate mouse mast cells in vitro and in vivo through a single receptor, Mrgprb2, the orthologue of the human G-protein-coupled receptor MRGPRX2. Secretagogue-induced histamine release, inflammation and airway contraction are abolished in Mrgprb2-null mutant mice. Furthermore, we show that most classes of US Food and Drug Administration (FDA)-approved peptidergic drugs associated with allergic-type injection-site reactions also activate Mrgprb2 and MRGPRX2, and that injection-site inflammation is absent in mutant mice. Finally, we determine that Mrgprb2 and MRGPRX2 are targets of many small-molecule drugs associated with systemic pseudo-allergic, or anaphylactoid, reactions; we show that drug-induced symptoms of anaphylactoid responses are significantly reduced in knockout mice; and we identify a common chemical motif in several of these molecules that may help predict side effects of other compounds. These discoveries introduce a mouse model to study mast cell activation by basic secretagogues and identify MRGPRX2 as a potential therapeutic target to reduce a subset of drug-induced adverse effects.
more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Autoimmune Encephalitis—Antibody Targets and Their Potential Pathogenicity in Immunotherapy-responsive Syndromes

Autoimmune Encephalitis—Antibody Targets and Their Potential Pathogenicity in Immunotherapy-responsive Syndromes | Immunopathology & Immunotherapy | Scoop.it
European Neurological Review, 2014;9(1):87–92


Alfredo Corell's insight:
Abstract:

Autoimmune encephalitis (AIE) associated with neural autoantibodies is increasingly recognized as a cause of subacute onset amnesia, confusion, and seizures. In the past decade, several key antibody targets have been identified in AIE. These include the N-methyl D-aspartate (NMDA) receptors, voltage-gated potassium channel complexes—in particular leucine-rich glioma inactivated 1 (LGI1) and glutamic acid decarboxylase (GAD). There is accumulating clinical and laboratory evidence that antibodies targeting the extracellular domains of cell-surface molecules are directly pathogenic. Each antibody target associates with a spectrum of clinical features and relative response to immunotherapies. These immunotherapies have been shown to improve short- and long-term clinical outcomes in affected patients. AIE is an important differential diagnosis to consider in patients presenting with symptoms of encephalitis as early diagnosis can lead to successful treatment.

2013 Citation European Neurological Review, 2014;9(1):87–92
Correspondence: Sarosh R Irani, DPhil, MRCP (Neurol), Level 6, West Wing, John Radcliffe Hospital, Oxford, OX3 9DS, UK. E: sarosh.irani@ndcn.ox.ac.uk
more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

CDC e-HAP FYI Updates: National Gay Mens's HIV/AIDS Awareness Day

CDC e-HAP FYI Updates: National Gay Mens's HIV/AIDS Awareness Day | Immunopathology & Immunotherapy | Scoop.it
Alfredo Corell's insight:
  •  Reasons/Razones is a bilingual campaign that encourages HIV testing among Latino gay and bisexual men.
more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Cancer Immunotherapy: the role of PD-1 and PD-L1

Dan Chen MD, PhD from Stanford Medical Oncology and Genentech describes brilliantly how our immune system detects cancer cells and how tumors get past our im...
Alfredo Corell's insight:

An awesome, simple and understandable animation about the use of PD-1 and PD-L1 interactions in cancer immunotherapy.


A must see!!! Brilliant way to understand the effects of checkpoint inhibitors and cancer immunotherapy.

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition | Immunopathology & Immunotherapy | Scoop.it
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK ...
Nature.com
Alopecia areata (AA) is a common autoimmune disease resulting from damage of the hair follicle by T cells.
Alfredo Corell's insight:
Nature Medicine (2014) doi:10.1038/nm.3645
Alopecia areata (AA) is a common autoimmune disease resulting from damage of the hair follicle by T cells. The immune pathways required for autoreactive T cell activation in AA are not defined limiting clinical development of rational targeted therapies1. Genome-wide association studies (GWAS)2 implicated ligands for the NKG2D receptor (product of the KLRK1 gene) in disease pathogenesis. Here, we show that cytotoxic CD8+NKG2D+ T cells are both necessary and sufficient for the induction of AA in mouse models of disease. Global transcriptional profiling of mouse and human AA skin revealed gene expression signatures indicative of cytotoxic T cell infiltration, an interferon-γ (IFN-γ) response and upregulation of several γ-chain (γc) cytokines known to promote the activation and survival of IFN-γ–producing CD8+NKG2D+ effector T cells. Therapeutically, antibody-mediated blockade of IFN-γ, interleukin-2 (IL-2) or interleukin-15 receptor β (IL-15Rβ) prevented disease development, reducing the accumulation of CD8+NKG2D+ T cells in the skin and the dermal IFN response in a mouse model of AA. Systemically administered pharmacological inhibitors of Janus kinase (JAK) family protein tyrosine kinases, downstream effectors of the IFN-γ and γc cytokine receptors, eliminated the IFN signature and prevented the development of AA, while topical administration promoted hair regrowth and reversed established disease. Notably, three patients treated with oral ruxolitinib, an inhibitor of JAK1 and JAK2, achieved near-complete hair regrowth within 5 months of treatment, suggesting the potential clinical utility of JAK inhibition in human AA.
more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Personalized medicine against hereditary immunodeficiency

Personalized medicine against hereditary immunodeficiency | Immunopathology & Immunotherapy | Scoop.it
Researchers have found a method to repair the gene mutation causing agammaglobulinemia, an immunodeficiency disease that almost exclusively affects boys and in which the body lacks the ability to produce immunoglobulins (gamma globulin). The disease is characterized by recurring bacterial infections, mainly in the respiratory system, and persons who suffer from the illness currently need life-long gamma globulin treatment.
Alfredo Corell's insight:

X-linked agammaglobulinemia (XLA) is an inherited immunodeficiency that results from mutations within the gene encoding Bruton’s tyrosine kinase (BTK). Many XLA-associated mutations affect splicing of BTK pre-mRNA and severely impair B cell development. Here, we assessed the potential of antisense, splice-correcting oligonucleotides (SCOs) targeting mutated BTK transcripts for treating XLA. Both the SCO structural design and chemical properties were optimized using 2′-O-methyl, locked nucleic acid, or phosphorodiamidate morpholino backbones. In order to have access to an animal model of XLA, we engineered a transgenic mouse that harbors a BAC with an authentic, mutated, splice-defective human BTK gene. BTK transgenic mice were bred onto a Btk knockout background to avoid interference of the orthologous mouse protein. Using this model, we determined that BTK-specific SCOs are able to correct aberrantly spliced BTK in B lymphocytes, including pro–B cells. Correction of BTK mRNA restored expression of functional protein, as shown both by enhanced lymphocyte survival and reestablished BTK activation upon B cell receptor stimulation. Furthermore, SCO treatment corrected splicing and restored BTK expression in primary cells from patients with XLA. Together, our data demonstrate that SCOs can restore BTK function and that BTK-targeting SCOs have potential as personalized medicine in patients with XLA.


GO TO THE JOURNAL OF CLINICAL INVESTIGATION MANUSCRIPT:

http://www.jci.org/articles/view/76175

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009 — NEJM

Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009 — NEJM | Immunopathology & Immunotherapy | Scoop.it
Original Article from The New England Journal of Medicine — Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009
Alfredo Corell's insight:

Sung-Yun Pai, M.D., Brent R. Logan, Ph.D., Linda M. Griffith, M.D., Ph.D., Rebecca H. Buckley, M.D., Roberta E. Parrott, B.S., Christopher C. Dvorak, M.D., Neena Kapoor, M.D., Imelda C. Hanson, M.D., Alexandra H. Filipovich, M.D., Soma Jyonouchi, M.D., Kathleen E. Sullivan, M.D., Ph.D., Trudy N. Small, M.D., Lauri Burroughs, M.D., Suzanne Skoda-Smith, M.D., Ann E. Haight, M.D., Audrey Grizzle, M.P.H., Michael A. Pulsipher, M.D., Ka Wah Chan, M.D., Ramsay L. Fuleihan, M.D., Elie Haddad, M.D., Ph.D., Brett Loechelt, M.D., Victor M. Aquino, M.D., Alfred Gillio, M.D., Jeffrey Davis, M.D., Alan Knutsen, M.D., Angela R. Smith, M.D., Theodore B. Moore, M.D., Marlis L. Schroeder, M.D., Frederick D. Goldman, M.D., James A. Connelly, M.D., Matthew H. Porteus, M.D., Ph.D., Qun Xiang, M.S., William T. Shearer, M.D., Ph.D., Thomas A. Fleisher, M.D., Donald B. Kohn, M.D., Jennifer M. Puck, M.D., Luigi D. Notarangelo, M.D., Morton J. Cowan, M.D., and Richard J. O'Reilly, M.D.

N Engl J Med 2014; 371:434-446July 31, 2014DOI: 10.1056/NEJMoa1401177

CONCLUSIONS

Transplants from donors other than matched siblings were associated with excellent survival among infants with SCID identified before the onset of infection. All available graft sources are expected to lead to excellent survival among asymptomatic infants. (Funded by the National Institute of Allergy and Infectious Diseases and others.)

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Vasoactive Intestinal Peptide Inhibits Pathogenic Th17 Cells

Vasoactive Intestinal Peptide Inhibits Pathogenic Th17 Cells | Immunopathology & Immunotherapy | Scoop.it
A study showing that vasoactive intestinal peptide (VIP) is able to reduce the pathogenic profile of Th17 cells and favoring Treg cell differentiation.
Alfredo Corell's insight:

These results indicate that VIP may have promising effects in the early phase of RA targeting the inhibition of pathogenic Th17 cells,and favoring Treg cell differentiation.

Source: Journal of Leukocyte Biology, 2015. DOI: 10.1189/jlb.3A0714-327R
Read more: Journal of Leukocyte Biology

See also: IL-17: A Promising Therapeutic Target in Several Chronic Inflammatory Diseases
Important New Features and Glucocorticoid-Resistance of Pro-Inflammatory Th17 Cells

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Hematologic Malignancies (classification, treatments and much more)

Hematologic Malignancies (classification, treatments and much more) | Immunopathology & Immunotherapy | Scoop.it
Hematologic Malignancies [6.2] Writer and Curator:  Larry H. Bernstein, MD, FCAP Hematologic Malignancies  Not excluding lymphomas [solid tumors] The following series of articles are discussions of...
Alfredo Corell's insight:

The following series of articles are discussions of current identifications, classification, and treatments of leukemias, myelodysplastic syndromes and myelomas.

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

March 27 wear Yellow to support Boy with SCID

March 27 wear Yellow to support Boy with SCID | Immunopathology & Immunotherapy | Scoop.it

A 5-year-old boy confined to a hospital room due to SCID (a rare immune disorder) is asking people to wear yellow in a show of support before his next operation — and the response on social media has been overwhelming, his family says.

Alfredo Corell's insight:

He asked supporters to wear his favorite color on March 27, before he undergoes a second bone marrow operation, and post the photos online with the hashtag #WearYellowForSeth. Seth’s family, from Northamptonshire, England, has been chronicling his time at the hospital on their blog, “Our Little Hero.” 

more...
No comment yet.
Rescooped by Alfredo Corell from PRG HAWAII NEWS WITH RUSS ROBERTS
Scoop.it!

Hawaii begins newborn screening for life-threatening immunodeficiencies

Hawaii begins newborn screening for life-threatening immunodeficiencies | Immunopathology & Immunotherapy | Scoop.it
Hawaii now universally screens for all disorders on the U.S. Department of Health and Human Service Recommended Uniform Screening Panel.

Via Russell Roberts
Alfredo Corell's insight:

A new STEP for newborn screening of PIDs worldwide :)


“While this condition is rare, it can have serious life-threatening consequences for newborn infants,” said Sylvia Mann, DOH Genomics Section Supervisor. “Fortunately, early screening can identify this and other inherited conditions, giving newborns a chance for life-saving treatment.”

more...
Russell Roberts's curator insight, March 5, 12:17 PM

This test could save the life of your child.  Aloha, Russ.

Scooped by Alfredo Corell
Scoop.it!

Caso 47 de enfermedades infecciosas -

Caso 47 de enfermedades infecciosas - | Immunopathology & Immunotherapy | Scoop.it
Descripción de un caso de infección pulmonar por mycobacterium bovis, revisión muy breve de las guías de diagnóstico, aislamiento y tratamiento de tuberculosis en nuestro medio
Alfredo Corell's insight:
Continuamos el caso clínico presentado por el Dr. Albert Figueras del Servicio de Medicina Intensiva del Hospital Son Espases. Esta semana, para intentar no realizar un spolier del caso clínico a quienes no lo hayan leído todavía no incluiremos la solución en el título del post. 

Todavía estáis a tiempo de intentar responder a las preguntas del caso clínico [aquí]


Presentación y resultados del caso clínico

- See more at: http://www.infectosos.com/2015/01/caso-47-solucionado-incluye-revision-de.html#sthash.6UJmezzD.dpuf

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

HELP SAVING LIVES: ¿Nos ayudas a demostrar cómo un té previene diarreas producidas por bacterias? how a tea can prevent infectious diarrhea?

HELP SAVING LIVES: ¿Nos ayudas a demostrar cómo un té previene diarreas producidas por bacterias? how a tea can prevent infectious diarrhea? | Immunopathology & Immunotherapy | Scoop.it

YOU CAN SAVE THOUSAND LIVES BY COLLABORATING IN THIS PROJECT:  a tea can prevent infectious diarrhea?

SALVA MILES E VIDAS

¿Nos ayudas a demostrar cómo un té previene diarreas producidas por bacterias?

Alfredo Corell's insight:

Globalmente, la diarrea causa la muerte de un millón de niños cada año. El 30% de las diarreas infecciosas son debidas a una bacteria patógena Escherichia coli. Este grupo de trabaho hadescubierto cómo una infusión podría ser útil para prevenir y tratar dichas infecciones... salvando miles de vidas en algunos países.

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Parasitology_ Illustrated Blog | AN OPEN FORUM FOR WHAT'S NEW AND RELEVANT IN PARASITOLOGY

Parasitology_ Illustrated Blog | AN OPEN FORUM FOR WHAT'S NEW AND RELEVANT IN PARASITOLOGY | Immunopathology & Immunotherapy | Scoop.it

This site continues to evolve as the science of parasitology is always evolving. Every effort has been made to provide the most up to date information available. That being said, Parasitology Illustrated is not liable for any misinformation that may be contained on the site. Please contact us if there is an error found. We will research it and gladly correct the error if appropriate.

Alfredo Corell's insight:

Excellent blog, plenty of well documented, classified information.

Also including Clinical Cases to help studing

A must visit

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Prevention of Infections During Primary Immunodeficiency

Prevention of Infections During Primary Immunodeficiency | Immunopathology & Immunotherapy | Scoop.it
Alfredo Corell's insight:

Because infectious diseases are a major source of morbidity and mortality in the majority of patients with primary immunodeficiencies (PIDs), the application of a prophylactic regimen is often necessary. However, because of the variety of PIDs and pathogens involved, and because evidence is scarce, practices are heterogeneous. To homogenize practices among centers, the French National Reference Center for PIDs aimed at elaborating recommendations for anti-infectious prophylaxis for the most common PIDs. We performed a literature review of infectious complications and prophylactic regimens associated with the most frequent PIDs. Then, a working group including different specialists systematically debated about chemoprophylaxis, immunotherapy, immunization, and recommendations for patients. Grading of prophylaxis was done using strength of recommendations (decreasing from A to D) and evidence level (decreasing from I to III). These might help infectious diseases specialists in the management of PIDs and improving the outcome of patients with PIDs.

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and beyond

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and beyond | Immunopathology & Immunotherapy | Scoop.it

OncLive
Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and beyond


Sagar B. Kudchodkar, PhD, and Marcela V. Maus, MD, PhD
Published Online: Friday, August 29, 2014
Alfredo Corell's insight:
Abstract

Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy in which the patient’s own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient. Clinical trials of CAR T cells directed to the CD19 antigen have shown impressive results in advanced B-cell malignancies at multiple academic centers over the last 3 years. We describe the technology of CAR T cells, findings at 5 academic centers, and toxicities associated with CAR T cell-treatment and their management. Although CAR T cells for B-cell malignancies are the most advanced in terms of clinical testing, CAR T cells are the basis of a new platform technology that is poised to be expanded to other hematologic and nonhematologic malignancies, especially as new targets are identified and manufacturing processes are streamlined.
  - See more at: http://www.onclive.com/publications/contemporary-oncology/2014/August-2014/Chimeric-Antigen-Receptor-CAR-T-Cell-Immunotherapy-for-Leukemia-and-Beyond?__scoop_post=3c482f60-3053-11e4-b39b-842b2b775358&__scoop_topic=827181#__scoop_post=3c482f60-3053-11e4-b39b-842b2b775358&__scoop_topic=827181

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

The prevalence of thyroid autoimmunity in patients with urticaria: a systematic review and meta-analysis

The prevalence of thyroid autoimmunity in patients with urticaria: a systematic review and meta-analysis | Immunopathology & Immunotherapy | Scoop.it
The prevalence of thyroid autoimmunity in patients with #urticaria: a systematic review and meta-analysis. http://t.co/RLgLl7jRna
Alfredo Corell's insight:
ENDOCRINE, July 27th, 2014


The meta-analysis results showed that the prevalence of positive thyroid autoantibodies in patients with urticaria was higher than non-urticaria controls (TgAb: OR 6.55, 95 % CI 3.19–13.42, P < 0.00001, I 2 = 67 %; TmAb: OR 4.51, 95 % CI 2.78–7.33, P < 0.00001, I 2 = 47 %; TPOAb: OR 8.71, 95 % CI 6.89–11.01,P < 0.00001, I 2 = 20 %, respectively). The results of this meta-analysis suggested that patients with urticaria were more likely to have thyroid autoimmunity than the control groups.

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

With So Many Terrific New Drugs For Chronic Lymphocytic Leukemia, Why Worry?

With So Many Terrific New Drugs For Chronic Lymphocytic Leukemia, Why Worry? | Immunopathology & Immunotherapy | Scoop.it
Forbes
With So Many Terrific New Drugs For Chronic Lymphocytic Leukemia, Why Worry?
Forbes
It's hard to keep track of practice-changing drugs for chronic lymphocytic leukemia (CLL).
Alfredo Corell's insight:

It’s hard to keep track of practice-changing drugs for chronic lymphocytic leukemia (CLL). Since last November, the FDA has approved three new agents and expanded indications for another to treat this indolent cancer of white blood cells. As someone who spent over ten years studying this form of leukemia, I’m thrilled by the science behind these targeted medicines, and by the potentially life-saving new options for people with this condition.



more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Newborn Screening for Severe Combined Immunodeficiency

Newborn Screening for Severe Combined Immunodeficiency | Immunopathology & Immunotherapy | Scoop.it
Opinion from JAMA — Newborn Screening for Severe Combined Immunodeficiency — Progress and Challenges (RT @JAMA_current: #Newborn Screening for Severe Combined #Immunodeficiency http://t.co/opTP3izQBP...
Alfredo Corell's insight:

September 30, 2014, marks the 50th anniversary of the Children’s Bureau recommendation for “the screening of all newborn infants for PKU [phenylketonuria] on a routine basis.”1 By 1968, 43 states had made screening for PKU mandatory.1 As a result of technological advances, newborn screening in the United States has been extended to as many as 37 core conditions in some states.2 As reported by Kwan and colleagues3 in this issue of JAMA, newborn screening for severe combined immunodeficiency (SCID) has been undertaken in 23 states and the Navajo Nation, beginning in Wisconsin in January 2008. The authors present data on more than 3 million newborns screened with a T-cell receptor excision circle (TREC) assay followed by confirmatory flow cytometry from 11 of these programs (10 states and the Navajo Nation).

more...
No comment yet.
Scooped by Alfredo Corell
Scoop.it!

Are complement deficiencies really rare? Overview on prevalence,
clinical importance and modern diagnostic approach

Are complement deficiencies really rare? Overview on prevalence,<br/>clinical importance and modern diagnostic approach | Immunopathology & Immunotherapy | Scoop.it
http://www.bragid.org.br/_download/artigos/are_complement_def_rare.pdf
Alfredo Corell's insight:

Complement deficiencies comprise between 1 and 10% of all primary immunodeficiencies (PIDs) accord-ing to national and supranational registries. They are still considered rare and even of less clinicalimportance. This not only reflects (as in all PIDs) a great lack of awareness among clinicians and gen-eral practitioners but is also due to the fact that only few centers worldwide provide a comprehensivelaboratory complement analysis. To enable early identification, our aim is to present warning signs forcomplement deficiencies and recommendations for diagnostic approach. The genetic deficiency of anyearly component of the classical pathway (C1q, C1r/s, C2, C4) is often associated with autoimmune dis-eases whereas individuals, deficient of properdin or of the terminal pathway components (C5 to C9), arehighly susceptible to meningococcal disease. Deficiency of C1 Inhibitor (hereditary angioedema, HAE)results in episodic angioedema, which in a considerable number of patients with identical symptomsalso occurs in factor XII mutations. New clinical entities are now reported indicating disease associa-tion with partial complement defects or even certain polymorphisms (factor H, MBL, MASPs). Mutationsaffecting the regulators factor H, factor I, or CD46 and of C3 and factor B leading to severe dysregulationof the alternative pathway have been associated with renal disorders, such as atypical hemolytic uremicsyndrome (aHUS) and – less frequent – with membranoproliferative glomerulonephritis (MPGN). Wesuggest a multi-stage diagnostic protocol starting based on the recognition of so called warning signswhich should aid pediatricians and adult physicians in a timely identification followed by a step-wisecomplement analysis to characterize the defect at functional, protein and molecular level.© 2014 Published by Elsevier 

more...
No comment yet.